Erudio Healtherudio.com
Drug
Etoposide trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying etoposide: DAREON-NEC-1 and KEYVIBE-008. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 37 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| KEYVIBE-008 NCT05224141 · Merck Sharp & Dohme LLC | first-line extensive-stage small cell lung cancer | Phase 3 | 83 | 17 | Focused | Nov 15, 2026 | Preview |
| DAREON-NEC-1 NCT07544654 · Boehringer Ingelheim | first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas | Phase 3 | 58 | 6 | Focused | Nov 15, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IMpower133 NCT02763579 · Hoffmann-La Roche DeepView → | untreated extensive-stage small cell lung cancer | Phase 3 | Deep | View | |||
| IMforte NCT05091567 · Hoffmann-La Roche DeepView → | extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| ZUMA-1 NCT02348216 · Kite, A Gilead Company DeepView → | refractory large B-cell lymphoma | Phase 1/Phase 2 | Deep | View | |||
| NRG-LU005 NCT03811002 · National Cancer Institute (NCI) DeepView → | limited-stage small cell lung cancer | Phase 3 | Deep | View | |||
| SKYSCRAPER-02 NCT04256421 · Hoffmann-La Roche DeepView → | untreated extensive-stage small cell lung cancer | Phase 3 | Deep | View | |||
| E1910 NCT02003222 · National Cancer Institute (NCI) DeepView → | newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia | Phase 3 | Deep | View | |||
| ZUMA-23 NCT05605899 · Kite, A Gilead Company DeepView → | first-line high-risk large B-cell lymphoma | Phase 3 | Deep | View | |||
| EA5181 NCT04092283 · National Cancer Institute (NCI) DeepView → | unresectable stage III non-small cell lung cancer | Phase 3 | Deep | View | |||
| KEYNOTE-604 NCT03066778 · Merck Sharp & Dohme LLC DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| DeLLphi-312 NCT07005128 · Amgen DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| AML-17 NCT00052299 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | previously untreated acute myeloid leukemia in older patients | Phase 3 | Deep | View | |||
| RTOG 1308 NCT01993810 · Radiation Therapy Oncology Group DeepView → | inoperable stage II-IIIB NSCLC | Phase 3 | Deep | View | |||
| AHOD2131 NCT05675410 · National Cancer Institute (NCI) DeepView → | newly diagnosed stage I/II classic Hodgkin lymphoma | Phase 3 | Deep | View | |||
| DAREON-7 NCT06132113 · Boehringer Ingelheim DeepView → | first-line advanced neuroendocrine carcinomas | Phase 1 | Deep | View | |||
| KEYNOTE-365 NCT02861573 · Merck Sharp & Dohme LLC DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| CALGB 50303 NCT00118209 · Alliance for Clinical Trials in Oncology DeepView → | untreated diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| KEYLYNK-012 NCT04380636 · Merck Sharp & Dohme LLC StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| CALGB 30610 NCT00632853 · Alliance for Clinical Trials in Oncology StandardView → | limited-stage small cell lung cancer | Phase 3 | Standard | View | |||
| AHOD1331 NCT02166463 · National Cancer Institute (NCI) StandardView → | newly diagnosed high-risk pediatric classical Hodgkin lymphoma | Phase 3 | Standard | View | |||
| S2409 NCT06769126 · SWOG Cancer Research Network StandardView → | extensive stage small cell lung cancer | Phase 2 | Standard | View | |||
| NICE NCT03016871 · City of Hope Medical Center StandardView → | relapsed or refractory Hodgkin lymphoma | Phase 2 | Standard | View | |||
| KEYVIBE-006 NCT05298423 · Merck Sharp & Dohme LLC StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| E2496 NCT00003389 · Eastern Cooperative Oncology Group StandardView → | locally extensive and advanced-stage Hodgkin lymphoma | Phase 3 | Standard | View | |||
| TREC NCT01165112 · University of Washington StandardView → | relapsed or refractory aggressive lymphoma | Phase 1/Phase 2 | Standard | View | |||
| ORCHARD NCT03944772 · AstraZeneca StandardView → | EGFR-mutated advanced NSCLC after first-line osimertinib | Phase 2 | Standard | View | |||
| AHOD0431 NCT00302003 · Children's Oncology Group FocusedView → | newly diagnosed low-risk childhood Hodgkin lymphoma | Phase 3 | Focused | View | |||
| P3BEP NCT02582697 · University of Sydney FocusedView → | intermediate and poor-risk metastatic germ cell tumors | Phase 3 | Focused | View | |||
| DeLLphi-303 NCT05361395 · Amgen FocusedView → | first-line extensive-stage small-cell lung cancer | Phase 1 | Focused | View | |||
| SEZanne NCT07155174 · AbbVie FocusedView → | previously untreated extensive-stage small cell lung cancer | Phase 2 | Focused | View | |||
| NCT06741644 NCT06741644 · CStone Pharmaceuticals FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| Total XVII NCT03117751 · St. Jude Children's Research Hospital FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| NCT03984448 NCT03984448 · National Cancer Institute (NCI) FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| SKYSCRAPER-02C NCT04665856 · Hoffmann-La Roche FocusedView → | untreated extensive-stage small cell lung cancer | Phase 3 | Focused | View | |||
| AHOD0831 NCT01026220 · Children's Oncology Group FocusedView → | Not given | Phase 3 | Focused | View | |||
| KEYNOTE-C11 NCT05008224 · Merck Sharp & Dohme LLC FocusedView → | newly diagnosed classical Hodgkin lymphoma | Phase 2 | Focused | View | |||
| NCT05142696 NCT05142696 · Novartis Pharmaceuticals FocusedView → | newly diagnosed extensive-stage small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT05624996 NCT05624996 · NRG Oncology FocusedView → | Not given | Phase 3 | Focused | View | |||